SmithDPrenticeRThompsonDHermanW. Association of exogenous estrogen and endometrial carcinoma. N. Engl. J. Med. 293, 1164–1167 (1975).
2.
SturdeeDWWade-EvansTPatersonMEThomMStuddJW. Relations between bleeding pattern, endometrial histology, and oestrogen treatment in menopausal women. BMJ1(6127), 1575–1577 (1978).
3.
PadwickMLPryse-DaviesJWhiteheadMI. A simple method for determining the optimal dosage of progestin in postmenopausal women receiving estrogens. N. Engl. J. Med. 315(15), 930–934 (1986).
4.
WhiteheadMITownsendPTPryse-DaviesJRyderTAKingRJ. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N. Engl. J. Med. 305(27), 1599–1605 (1981).
5.
al-AzzawiFHabibaM. Regular bleeding on hormone replacement therapy: a myth?Br. J. Obstet. Gynecol. 101(8), 661–662 (1994).
6.
HabibaMABellSCAbramsKal-AzzawiF. Endometrial responses to hormone replacement therapy: the bleeding pattern. Hum. Reprod. 11(3), 503–508 (1996).
EttingerBLiDKKleinR. Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy: comparison of cyclic versus continuous combined schedules. Fertil. Steril. 69(5), 865–869 (1998).
9.
SturdeeDWBarlowDHUlrichLG. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestogen replacement therapy? UK Continuous Combined HRT Study Investigators. Lancet344(8928), 979–982 (1994).
10.
DennersteinLFotherbyKBurrowsGDLabyBWoodC. Plasma levels of ethinyl oestradiol and norgestrel during hormone replacement therapy. Maturitas2(2), 147–154 (1980).
JarvelaITekayAJouppilaP. The effect of a levonorgestrel-releasing intrauterine system on uterine artery blood flow, hormone concentrations and ovarian cyst formation in fertile women. Hum. Reprod. 13 (12), 3379–3383 (1998).
13.
EttingerBPressmanA. Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy. Am. J. Manag. Care5(6), 779–785 (1999).
14.
RossouwJEAndersonGLPrenticeRL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA288(3), 321–333 (2002).
15.
PrenticeRLPettingerMAndersonGL. Statistical issues arising in the Women's Health Initiative. Biometrics61(4), 899–911, discussion 911–941 (2005).
16.
ShapiroS. The Million Women Study: potential biases do not allow uncritical acceptance of the data. Climacteric7(1), 3–7 (2004).
17.
ShapiroS. Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy: detection bias and resolution of discrepant findings in two Women's Health Initiative studies. Climacteric9(6), 416–420 (2006).
18.
LaCroixAZChlebowskiRTMansonJE. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA305(13), 1305–1314 (2011).
19.
AndersonGLLimacherMAssafAR. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA291(14), 1701–1712 (2004).
20.
ShumakerSALegaultCRappSR. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA289(20), 2651–2662 (2003).
21.
ShumakerSALegaultCKullerL. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA291(24), 2947–2958 (2004).
22.
SöderqvistGIsakssonEvon SchoultzBCarlströmKTaniESkoogL. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am. J. Obstet. Gynecol. 176(1 Pt 1), 123–128 (1997).
23.
Morales-MedinaJCSanchezFFloresGDumontYQuirionR. Morphological reorganization after repeated corticosterone administration in the hippocampus, nucleus accumbens and amygdala in the rat. J. Chem. Neuroanat. 38(4), 266–272 (2009).
24.
StarkmanMNGebarskiSSBerentSSchteingartDE. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome. Biol. Psychiatry32(9), 56–765 (1992).
25.
WolkowitzOM. Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroids. Psychoneuroendocrinology19(3), 233–255 (1994).
MiyagawaKRöschJStanczykFHermsmeyerK. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat. Med. 3(3), 324–327 (1997).
28.
StringerEMLevyJSinkalaM. HIV disease progression by hormonal contraceptive method: secondary analysis of a randomized trial. AIDS23(11), 1377–1382 (2009).
29.
MüngerKPhelpsWCBubbVHowleyPMSchlegelR. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63(10), 4417–4421 (1989).
30.
HsiaJLangerRDMansonJE. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch. Intern. Med. 166(3), 357–365 (2006).
31.
ZandiPPCarlsonMCPlassmanBL. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA288(17), 2123–2129 (2002).
32.
Al-AzzawiFWahabMThompsonJWhiteheadMThompsonW. Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: a dose-ranging study. Hum. Reprod. 14(3), 636–641 (1999).
